Literature DB >> 33451174

An EUA for casirivimab and imdevimab for COVID-19.

.   

Abstract

Entities:  

Keywords:  COVID-19; adverse effects; casirivimab; coronavirus; dosage; efficacy; imdevimab; safety

Year:  2020        PMID： 33451174

Source DB:  PubMed          Journal:  Med Lett Drugs Ther        ISSN： 0025-732X            Impact factor:   1.909


× No keyword cloud information.
  18 in total

1.  Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19.

Authors:  Ravindra Ganesh; Colin F Pawlowski; John C O'Horo; Lori L Arndt; Richard F Arndt; Sarah J Bell; Dennis M Bierle; Molly Destro Borgen; Sara N Hanson; Alexander Heyliger; Jennifer J Larsen; Patrick J Lenehan; Robert Orenstein; Arjun Puranik; Leigh L Speicher; Sidna M Tulledge-Scheitel; A J Venkatakrishnan; Caroline G Wilker; Andrew D Badley; Raymund R Razonable
Journal:  J Clin Invest       Date:  2021-10-01       Impact factor: 14.808

2.  Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019.

Authors:  Raymund R Razonable; Ravindra Ganesh; Rachel K Bishop; Tracy L Culbertson; Molly Destro Borgen; Michelle C Hedin; Laura H Hopkins; Tammy A Jackson; Jennifer J Larsen; Jennifer A Matoush; Darcie E Moehnke; Shelly M Olson; Kellie M Peterson; Jordan Rosedahl; Lindsey M Philpot
Journal:  J Patient Exp       Date:  2022-06-23

3.  Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.

Authors:  Raymund R Razonable; John C O'Horo; Douglas W Challener; Lori Arndt; Richard F Arndt; Caroline G Clune; Tracy L Culbertson; Scott T Hall; Alexander Heyliger; Tammy A Jackson; Brian D Kennedy; Jennifer Larsen; Sara N Hanson; Perry W Sweeten; Sidna M Tulledge-Scheitel; Ravindra Ganesh
Journal:  Mayo Clin Proc       Date:  2022-06-23       Impact factor: 11.104

4.  Monoclonal Antibody Therapy for COVID-19: A Public Health Perspective From Arkansas.

Authors:  Atul Kothari; Elizabeth Woodland Borella; Michelle R Smith
Journal:  Open Forum Infect Dis       Date:  2022-01-10       Impact factor: 3.835

Review 5.  An overview on the current available treatment for COVID-19 and the impact of antibiotic administration during the pandemic.

Authors:  H S C Paula; S B Santiago; L A Araújo; C F Pedroso; T A Marinho; I A J Gonçalves; T A P Santos; R S Pinheiro; G A Oliveira; K A Batista
Journal:  Braz J Med Biol Res       Date:  2021-12-10       Impact factor: 2.590

Review 6.  The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic.

Authors:  Sylvia Annabel Dass; Venugopal Balakrishnan; Norsyahida Arifin; Crystale Siew Ying Lim; Fazlina Nordin; Gee Jun Tye
Journal:  Front Immunol       Date:  2022-02-15       Impact factor: 7.561

7.  Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.

Authors:  John O'Horo; Douglas W Challener; Ryan J Anderson; Richard F Arndt; Sara E Ausman; Scott T Hall; Alexander Heyliger; Brian D Kennedy; Perry W Sweeten; Ravindra Ganesh; Raymund R Razonable
Journal:  Mayo Clin Proc       Date:  2022-02-23       Impact factor: 11.104

Review 8.  HIV and COVID-19: Lessons From HIV and STI Harm Reduction Strategies.

Authors:  Ronnie M Gravett; Jeanne M Marrazzo
Journal:  Curr HIV/AIDS Rep       Date:  2021-06-08       Impact factor: 5.071

9.  Safety and Tolerability of Monoclonal Antibody Therapies for Treatment of COVID-19 in Pediatric Patients.

Authors:  Gregory Mak; Aimee M Dassner; Benjamin M Hammer; Benjamin R Hanisch
Journal:  Pediatr Infect Dis J       Date:  2021-12-01       Impact factor: 3.806

10.  Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19.

Authors:  Brandon J Webb; Whitney Buckel; Todd Vento; Allison M Butler; Nancy Grisel; Samuel M Brown; Ithan D Peltan; Emily S Spivak; Mark Shah; Theadora Sakata; Anthony Wallin; Eddie Stenehjem; Greg Poulsen; Joseph Bledsoe
Journal:  Open Forum Infect Dis       Date:  2021-06-23       Impact factor: 3.835
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.